ChromaDex (CDXC) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
ChromaDex Corporation Reports First Quarter 2020 Financial Results
May 11, 2020 4:01 PM EDTFirst Quarter 2020 Highlights vs. First Quarter 2019
Strong growth in net sales to $14.3 million, higher gross margins, and significantly improved marketing efficiency year-over-year. Tru Niagen net sales of $11.1 million, a 50% increase year-over-year. Net loss was ($5.9) million or ($0.10) per share, an improvement of $0.05 per share year over year. Adjusted EBITDA excluding total legal expense, a non-GAAP measure, was a loss of ($0.3) million, a $2.4 million improvement year-over-year. Launched Tru Niagen online in Australia with distribution partner, Matakana Health Limited, and online through... More